Logo image of TGTX

TG THERAPEUTICS INC (TGTX) Stock Overview

USA - NASDAQ:TGTX - US88322Q1085 - Common Stock

34.55 USD
+0.86 (+2.55%)
Last: 10/28/2025, 8:24:22 PM
34.5 USD
-0.05 (-0.14%)
After Hours: 10/28/2025, 8:24:22 PM

TGTX Key Statistics, Chart & Performance

Key Statistics
Market Cap5.48B
Revenue(TTM)454.07M
Net Income(TTM)60.46M
Shares158.67M
Float143.22M
52 Week High46.48
52 Week Low22.92
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.37
PE93.38
Fwd PE18.21
Earnings (Next)10-30 2025-10-30
IPO1995-12-14
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


TGTX short term performance overview.The bars show the price performance of TGTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15 -20

TGTX long term performance overview.The bars show the price performance of TGTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400

The current stock price of TGTX is 34.55 USD. In the past month the price decreased by -4.36%. In the past year, price increased by 28.44%.

TG THERAPEUTICS INC / TGTX Daily stock chart

TGTX Latest News, Press Relases and Analysis

TGTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.49 401.96B
AMGN AMGEN INC 13.39 157.25B
GILD GILEAD SCIENCES INC 15.23 146.27B
VRTX VERTEX PHARMACEUTICALS INC 24.93 108.30B
REGN REGENERON PHARMACEUTICALS 14.54 69.37B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 62.38B
ARGX ARGENX SE - ADR 90.81 51.50B
INSM INSMED INC N/A 34.94B
ONC BEONE MEDICINES LTD-ADR 5.1 34.80B
NTRA NATERA INC N/A 26.02B
BNTX BIONTECH SE-ADR N/A 25.25B
BIIB BIOGEN INC 9.31 21.86B

About TGTX

Company Profile

TGTX logo image TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 370 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

Company Info

TG THERAPEUTICS INC

3020 Carrington Mill Blvd., Suite 475

Morrisville NORTH CAROLINA 10014 US

CEO: Michael S. Weiss

Employees: 370

TGTX Company Website

TGTX Investor Relations

Phone: 18775758489

TG THERAPEUTICS INC / TGTX FAQ

What does TGTX do?

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 370 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.


Can you provide the latest stock price for TG THERAPEUTICS INC?

The current stock price of TGTX is 34.55 USD. The price increased by 2.55% in the last trading session.


What is the dividend status of TG THERAPEUTICS INC?

TGTX does not pay a dividend.


What is the ChartMill rating of TG THERAPEUTICS INC stock?

TGTX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What is the GICS sector and industry of TGTX stock?

TG THERAPEUTICS INC (TGTX) operates in the Health Care sector and the Biotechnology industry.


What is the market capitalization of TGTX stock?

TG THERAPEUTICS INC (TGTX) has a market capitalization of 5.48B USD. This makes TGTX a Mid Cap stock.


What is the next earnings date for TGTX stock?

TG THERAPEUTICS INC (TGTX) will report earnings on 2025-10-30.


TGTX Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to TGTX. When comparing the yearly performance of all stocks, TGTX turns out to be only a medium performer in the overall market: it outperformed 68.78% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TGTX Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to TGTX. TGTX has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TGTX Financial Highlights

Over the last trailing twelve months TGTX reported a non-GAAP Earnings per Share(EPS) of 0.37. The EPS decreased by -38.33% compared to the year before.


Industry RankSector Rank
PM (TTM) 13.31%
ROA 8.6%
ROE 21.87%
Debt/Equity 0.89
Chartmill High Growth Momentum
EPS Q2Q%325%
Sales Q2Q%92.13%
EPS 1Y (TTM)-38.33%
Revenue 1Y (TTM)30.96%

TGTX Forecast & Estimates

15 analysts have analysed TGTX and the average price target is 43.18 USD. This implies a price increase of 24.98% is expected in the next year compared to the current price of 34.55.

For the next year, analysts expect an EPS growth of 451.63% and a revenue growth 83.46% for TGTX


Analysts
Analysts78.67
Price Target43.18 (24.98%)
EPS Next Y451.63%
Revenue Next Year83.46%

TGTX Ownership

Ownership
Inst Owners64.52%
Ins Owners9.73%
Short Float %16.62%
Short Ratio12.77